Buy Dcth Stock -

is currently positioned as a high-growth medical device company, with a consensus "Moderate Buy" or "Strong Buy" rating from Wall Street analysts. The company reached a financial turning point in 2025, recording its first year of net income and record-high revenues. Investment Thesis: Why Buy?

: Results from the CHOPIN Phase 2 trial showed significant survival improvements for liver treatment, which may support broader adoption and inclusion in clinical guidelines. Financial Snapshot & Market Performance Google's Finance Data buy dcth stock

: Delcath reported record 2025 revenue of $85.2 million , a significant increase from $37.2 million in 2024. This was primarily driven by its HEPZATO KIT , which saw a 144% year-over-year sales surge . is currently positioned as a high-growth medical device

: The company currently operates 28 active treatment centers and plans to expand to 40 centers by the end of 2026 . : Results from the CHOPIN Phase 2 trial

(function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){ (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o), m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m) })(window,document,'script','//www.google-analytics.com/analytics.js','ga'); ga('create', 'UA-61364310-1', 'auto'); ga('send', 'pageview');